Clinical trial
Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer
NCT00033735 · Eisai Inc., Industry · Completed
Key facts
| NCT number | NCT00033735 |
|---|---|
| Title | Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer |
| Official title | Phase III Trial Of Irofulven Vs. 5-Fluorouracil In Patients With Gemcitabine-Refractory Advanced Pancreatic Adenocarcinoma |
| Lead sponsor | Eisai Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | fluorouracil, Irofulven |
| Enrollment | 158 |
| Start date | Jan 1, 2000 |
| Primary completion | Jun 1, 2003 |
| First posted | Jan 15, 2004 |
| Last update posted | Dec 24, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: